doi: 10.1186/s13075-017-1283-3 92 LiJZuoLTianYHeYZhangZGuoPet al
In phase III trials in patients with type 2 diabetes, once-weekly subcutaneous administration of semaglutide has been shown to significantly improve glycaemic control and reduce body weight compared with placebo when given as monotherapy, and compared with sitagliptin, extended-release exenatide or insulin glargine when given as add-on therapy to oral antidiabetic drugs [5,6,7,8]
PubMed , Toxicological Sciences , vol
Common side effects include nausea, vomiting, and constipationespecially during dose escalationbut these usually improve over weeks
Z.DranseH
First, berberine is antimicrobial, so taking too high a dose may disrupt your gut microbiome (5)